Juvenescence Limited has successfully completed Phase 1 clinical evaluation of MDI-2517, its plasminogen activator inhibitor-1 (PAI-1) inhibitor candidate. The trial demonstrated favorable safety and tolerability profiles, with the compound supporting a once-daily oral dosing regimen. The positive findings establish a clinical foundation for progression to late-stage development activities.
In conjunction with the trial completion, Juvenescence has strengthened its clinical operations infrastructure through three senior-level appointments. Carmel Nanthakumar has joined as Vice President of Translational Biology, Paul Russell as Chief Development Officer, and Catherine McClinton as Head of Clinical Operations. The appointments reflect the company's commitment to advancing its pipeline through the subsequent development phases.
The company plans to initiate a Phase 2 proof-of-concept study in the second half of 2026, targeting patient populations with metabolic and fibrotic diseases. This progression aligns with the broader clinical development strategy for PAI-1 inhibition as a therapeutic approach in these disease areas.